Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5092164
Max Phase: Preclinical
Molecular Formula: C30H37N5
Molecular Weight: 467.66
Molecule Type: Unknown
Associated Items:
ID: ALA5092164
Max Phase: Preclinical
Molecular Formula: C30H37N5
Molecular Weight: 467.66
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CN(C)CCN(C)c1ccc(C#N)c(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)c1
Standard InChI: InChI=1S/C30H37N5/c1-32(2)16-17-33(3)29-15-14-27(23-31)28(22-29)24-34-18-20-35(21-19-34)30(25-10-6-4-7-11-25)26-12-8-5-9-13-26/h4-15,22,30H,16-21,24H2,1-3H3
Standard InChI Key: YTXTVBOJTSPSRG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 467.66 | Molecular Weight (Monoisotopic): 467.3049 | AlogP: 4.46 | #Rotatable Bonds: 9 |
Polar Surface Area: 36.75 | Molecular Species: BASE | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 8.91 | CX LogP: 5.25 | CX LogD: 3.18 |
Aromatic Rings: 3 | Heavy Atoms: 35 | QED Weighted: 0.46 | Np Likeness Score: -1.45 |
1. Wang Y, Li J, Tan J, Yang B, Quan Y, Peng Z, Li Y, Li Z.. (2022) Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors., 65 (3.0): [PMID:35050619] [10.1021/acs.jmedchem.1c01637] |
Source(1):